However, the development of S100 antibodies for cancer therapy is at its very beginning, and examples of other therapeutic antibodies showed that limited clinical efficacy, for example, due to lacking tumour tissue penetration, immune reactions, and antibody resistance [252], is an issue which might need to be overcome in the later stages of this process. This evidence concerns the gene S100B and cancer.